EMA Application withdrawn: Surfaxin (sinapultide;Dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol;palmitic acid) — Pharm Research Associates (UK) Limited

View source ↗

Summary

EMA withdrew the application for Surfaxin (sinapultide and lipid components) for Respiratory Distress Syndrome in newborns.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome Newborn

Drugs mentioned

• SURFAXIN (lucinactant)

Snippet

Status: Application withdrawn. Therapeutic area: Respiratory Distress Syndrome, Newborn. MAH: Pharm Research Associates (UK) Limited. Decision date: 31/12/2009. Orphan medicine